检索结果-南通市图书馆

Evaluation of setup errors in conformal radiotherapy for pelvic tumours: Case of the Regional center of oncology, Agadir

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Radiation Medicine and Protection 2020年第2期1卷 99-102页

作者： Bouchra Amaoui Abdellah Hadaoui Dounia Mouhssine Slimane Semghouli Radiotherapy Department Regional Center of Oncology AgadirMorocco Al Kindy Treatment center of oncology and Diagnosis Casablanca Morocco Higher Institute of Nursing Professions and Health Techniques Agadir Morocco

Context:The errors made during repetitive patient placements affect significantly the accuracy of treatment and the results of ***:To determine the total,systematic and random error in order to estimate the margin between the Clinical Target Volume(CTV)and the Planning Target Volume(PTV)in the pelvic *** and methods:Set up errors was estimated by superimposing a digitally reconstructed radiograph(DRR)as a reference image with an electronic portal image device(EPID).The total errors in the Medio-Lateral(ML),Cranio-Caudal(CC)and Antero-Posterior(AP)directions were compared by *** systematic and random errors,the ratio of variance(F statistic)was *** were calculated using Van Herk ***:208 images(80 DRRs and 128 EPIDs)were *** systematic error ranged from 1.93 to 2.01 mm,1.26 to 1.39 mm,and 1.20 to 2.94 mm in the x,y and z-axis,*** random error ranged from 2.33 to 2.90 mm,1.25 to 1.66 mm,and 1.04 to 1.28 *** PTV margin according to the Van Herk equation in the x,y and z directions was estimated to be 7.11,4.64 and 3.90 mm for the cervix uteri and a 6.47,4.03,and 3.70 mm for the ***:The use of weekly EPID/DRR allows estimating the setup of the planning target volume(PTV)expansion according to our *** this study,the evaluated set up margin was approximately 8 mm in the X-axis,5 mm in Y and Z axis for pelvic conformal radiotherapy.

关键词： radiotherapy pelvic conformal

Cohort study on the treatment of BRAF V600E mutant metastatic colorectal cancer with integrated Chinese and western medicine

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical oncology 2025年第1期16卷 25-33页

作者： Jiang-Yu Bian Yu-Fang Feng Wen-Ting He Tong Zhang Department of oncology Xiyuan Hospital of China Academy of Chinese Medical SciencesBeijing 100091China Department of oncology The Fourth Clinical Medical College of Xinjiang Medical UniversityUrumqi 830001China Department of oncology Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical UniversityUrumqi 830001China

BACKGROUND Patients with BRAF V600E mutant metastatic colorectal cancer(mCRC)have a low incidence rate,poor biological activity,suboptimal response to conventional treatments,and a poor *** the previous cohort study on mCRC conducted by our team,it was observed that integrated Chinese and Western medicine treatment could significantly prolong the overall survival(OS)of patients with colorectal ***,we further explored the survival benefits in the population with BRAF V600E mutant *** To evaluate the efficacy of integrated Chinese and Western medicine in the treatment of BRAF V600E mutant metastatic colorectal *** A cohort study was conducted on patients with BRAF V600E mutant metastatic colorectal cancer admitted to Xiyuan Hospital of China Academy of Chinese Medical Sciences and Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region from January 2016 to December *** patients were divided into two *** A total of 34 cases were included,with 23 in Chinese-Western medicine cohort(cohort A)and 11 in Western medicine cohort(cohort B).The median overall survival was 19.9 months in cohort A and 14.2 months in cohort B,with a statistically significant difference(P=0.038,hazard ratio=0.46).The 1-3-year survival rates were 95.65%(22/23),39.13%(9/23),and 26.09%(6/23)in cohort A,and 63.64%(7/11),18.18%(2/11),and 9.09%(1/11)in cohort B,*** analysis showed statistically significant differences in median OS between the two cohorts in the right colon,liver metastasis,chemotherapy,and first-line treatment subgroups(P<0.05).CONCLUSION Integrated Chinese and Western medicine can prolong the survival and reduce the risk of death in patients with BRAF V600E mutant metastatic colorectal cancer,with more pronounced benefits observed in patients with right colon involvement,liver metastasis,combined chemotherapy,and first-line treatment.

关键词： Metastatic colorectal cancer BRAF V600E mutation Integrated Chinese and Western medicine Cohort study

Our DREAM of defeating cancer: a summary of the 3rd Guangzhou International Symposium on oncology

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2014年第3期33卷 125-132页

作者： Wei-Wei Xiao Chao-Nan Qian Department of Radiation oncology Sun Yat-sen University Cancer Center State Key Laboratory of oncology in South China Collaborative Innovation center for Cancer Medicine Department of Nasopharyngeal Carcinoma Sun Yat-sen University Cancer Center

Every 6 seconds,someone dies from cancer somewhere in the *** 13 seconds,a cancer patient dies in *** is currently the biggest threat to life around the world and a critical burden to *** address this problem,it is especially important for scientists and physicians to remain abreast of cutting edge research and progress in the treatment of this *** 3rd Guangzhou International Symposium on oncology

关键词： Guangzhou seconds targeted someone metastasis currently threat colorectal chemotherapy DREAM

Radiation oncology practice during COVID-19 pandemic in developing countries

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2021年第25期9卷 7292-7296页

作者： Fawzi Abuhijla Ramiz Abuhijlih Issa Mohamad Department of Radiation oncology King Hussein Cancer CenterAmman 11941Jordan

Radiation therapy(RT)is considered one of the cornerstone modalities of treatment for different cancer *** preparation and delivery of RT requires a number of staff members from different disciplines within the radiation oncology *** the emergence of the corona virus disease 2019(COVID-19)pandemic,RT,similar to other cancer care modalities,has been adapted to minimize patient and staff exposure without compromising the oncological *** was reflected in the dramatic practice changes that occurred in the past year to address the lockdown restrictions and fulfill the infection control *** practices differ across regions based on financial and training levels,and developing countries with limited resources have struggled to maintain radiation treatment services at a level equivalent to that in developed countries while following pandemic control *** response during the COVID-19 pandemic varied between developing countries according to the infection rate and RT technological *** this editorial,we review recently published articles addressing radiotherapy practice reports during the COVID-19 pandemic in developing countries.

关键词： Radiotherapy COVID-19,Developing countries Radiation therapy Pandemic Low income countries

Chinese Society of Clinical oncology Breast Cancer(CSCO BC)guidelines in 2022:stratification and classification

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2022年第6期19卷 769-773页

作者： Jianbin Li Zefei Jiang Senior Department of oncology Fifth Medical Center of Chinese PLA General HospitalBeijing 100071China

In April 2017,the first edition Chinese Society of Clinical oncology Breast Cancer(CSCO BC)guidelines were *** guidelines were based on medical evidence,as well as the accessibility and cost effectiveness of various anticancer drugs in *** CSCO BC guidelines include regimens with a high level of evidence,good product accessibility and high consistent consensus among Chinese experts as level I *** with a high level of evidence but poor product accessibility or expert consensus are included as level II recommendations.

关键词： CSCO Breast Cancer

Potential of non-Western medicines in chemoradiotherapy for cervical cancer

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2025年第2期13卷 21-23页

作者： Takashi Ono Masashi Koto Department of Radiation oncology Faculty of MedicineYamagata UniversityYamagata 990-9585Japan

This editorial explores the potential integration of non-Western medicine into radiotherapy for cervical *** radiotherapy remains a radical treatment for cervical cancer,its associated toxicity and decline in quality of life can significantly impact patients’***,most treatments are supportive,with no specific treatment options available in Western ***-Western medicine,often less toxic and easier to administer,has shown promising results when used alongside radiotherapy for cervical *** these potential benefits,challenges such as limited evidence and restricted application areas *** non-Western medicines may offer potential improvements in chemoradiotherapy outcomes for cervical cancer,further research is necessary to substantiate these benefits.

关键词： Cervical cancer Radiotherapy Non-Western medicine Kampo Herbal medicine

Translational oncology toward benefiting cancer patients:the Sun Yat-sen University Cancer center experience

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2016年第10期59卷 1057-1062页

作者： Mathilde Guerin Chaonan Qian Qian Zhong Qian Cui Yunmiao Guo Jinxin Bei Jianyong Shao Xiaofeng Zhu Wenlin Huang Jiangxue Wu Ranyi Liu Qiang Liu Jing Wang Weihua Jia Xiaohui Zheng Yixin Zeng Sun Yat-sen University Cancer center Guangzhou 510060China

Cancer is a leading cause of death in China with an estima- tion of nearly 2 million deaths every year （Chen and Fu, 2011b）. Matter of a public health importance in China and worldwide, the scientific community is still facing many obstacles to eradicate cancer： complexity of a mul- ti-factorial disease with organ-based specificities, high fail- ure rate of many anti-cancer drugs in clinical trials, lack of understanding of the cancer genesis factors.

关键词：癌症患者中山大学肿瘤转化器官特异性多因子疾病公共卫生抗癌药物

Genetic signatures of ERCC1 and ERCC2 expression,along with SNPs variants,unveil favorable prognosis in SCLC patients undergoing platinum-based chemotherapy

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

oncology Research 2025年第1期33卷 45-55页

作者： ENRICO CALIMAN SARA FANCELLI FEDERICO SCOLARI ADRIANO PASQUI CLARA MANNESCHI DANIELE LAVACCHI FRANCESCA MAZZONI FRANCESCA GENSINI VALERIA PASINI CAMILLA EVA COMIN LUCA VOLTOLINI SERENA PILLOZZI LORENZO ANTONUZZO Clinical oncology Unit Careggi University HospitalFlorence50134Italy Department of Experimental and Clinical Medicine University of FlorenceFlorence50134Italy Department of Health Sciences University of FlorenceFlorence50134Italy Medical oncology Unit Careggi University HospitalFlorence50134Italy Department of Experimental and Clinical Biomedical Sciences“Mario Serio” University of FlorenceFlorence50134Italy Section of Anatomic Pathology Department of Health SciencesUniversity of FlorenceFlorence50139Italy Section of Surgery Histopathology and Molecular PathologyUniversity of FlorenceFlorence50139Italy Thoracic Surgery Unit Careggi University HospitalFlorence50134Italy

Background:Platinum chemotherapy(CT)remains the backbone of systemic therapy for patients with smallcell lung cancer(SCLC).The nucleotide excision repair(NER)pathway plays a central role in the repair of the DNA damage exerted by platinum *** in this repair mechanism may affect patients’*** and Methods:We conducted a retrospective analysis of data from 38 patients with extensive disease(ED)-SCLC who underwent platinum-CT at the Clinical oncology Unit,Careggi University Hospital,Florence(Italy),from 2015 to *** expression analysis and single nucleotide polymorphism(SNP)characterization of three NER pathway genes—namely ERCC1,ERCC2,and ERCC5—were performed on patient tumor ***:Overall,elevated expression of ERCC genes was observed in SCLC patients compared to healthy *** with low ERCC1 and ERCC5 expression levels exhibited a better median progression-free survival(mPFS=7.1 vs.4.9 months,p=0.39 for ERCC1 and mPFS=6.9 vs.4.8 months,p=0.093 for ERCC5)and overall survival(mOS=8.7 vs.6.0 months,p=0.4 for ERCC1 and mOS=7.2 vs.6.2 months,p=0.13 for ERCC5).Genotyping analysis of five SNPs of ERCC genes showed a longer survival in patients harboring the wild-type genotype or the heterozygous variant of the ERCC1 rs11615 SNP(p=0.24 for PFS and p=0.14 for OS)and of the rs13181 and rs1799793 ERCC2 SNPs(p=0.43 and p=0.26 for PFS and p=0.21 and p=0.16 for OS,respectively)compared to patients with homozygous mutant ***:The comprehensive analysis of ERCC gene expression and SNP variants appears to identify patients who derive greater survival benefits from platinum-CT.

关键词： Small cell lung cancer(SCLC) Nucleotide excision repair(NER)pathway ERCC genes Single nucleotide polymorphisms(SNPs) Platinumchemotherapy(CT)

Multimodality management of gallbladder cancer can lead to a better outcome:Experience from a tertiary care oncology centre in North India

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2021年第45期27卷 7813-7830页

作者： Shaifali Goel Abhishek Aggarwal Assif Iqbal Vineet Talwar Swarupa Mitra Shivendra Singh Department of GI and HPB Oncosurgery Rajiv Gandhi Cancer Institute and Research CenterDelhi 110085DelhiIndia Department of Medical oncology Rajiv Gandhi Cancer Institute and Research CenterDelhi 110085DelhiIndia Department of Radiation oncology Rajiv Gandhi Cancer Institute and Research CenterDelhi 110085DelhiIndia

BACKGROUND Surgical resection is a treatment of choice for gallbladder cancer(GBC)patients but only 10%of patients have a resectable disease at *** after surgical resection,overall survival(OS)has been poor due to high rates of *** of surgery and systemic therapy can improve outcomes in this aggressive *** To summarize our single-center experience with multimodality management of resectable GBC *** Data of all patients undergoing surgery for suspected GBC from January 2012 to December 2018 was retrieved from a prospectively maintained electronic *** extracted included demographics,operative and perioperative details,histopathology,neoadjuvant/adjuvant therapy,follow-up,and *** know the factors associated with recurrence and OS,univariate and multivariate analysis was done using log rank test and cox proportional hazard analysis for categorical and continuous variables,*** analysis was done using multiple regression *** Of 274 patients with GBC taken up for surgical resection,172(62.7%)were female and the median age was 56 *** exploration,102 patients were found to have a metastatic or unresectable disease(distant metastasis in 66 and locally unresectable in 34).Of 172 patients who finally underwent surgery,93(54%)underwent wedge resection followed by anatomical segment IVb/V resection in 66(38.4%)and modified extended right hepatectomy in 12(7%)*** postoperative mortality at 90 d was 4.6%.During a median follow-up period of 20 mo,71(41.2%)patients developed *** 1-,3-,and 5-years OS rates were 86.5%,56%,and 43.5%,*** 1-and 3-year disease free survival(DFS)rates were 75%and 49.2%,*** multivariate analysis,inferior OS was seen with pT3/T4 tumor(P=0.0001),perineural invasion(P=0.0096),and R+resection(P=0.0125).However,only pT3/T4 tumors were associated with a poor DFS(P<0.0001).CONCLUSION Multim

关键词： Gallbladder cancer Multimodality Surgical resection Adjuvant Chemotherapy Chemoradiotherapy